WESTBROOK, Maine, Jan. 26, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2022 fourth quarter and full year financial results for Monday, February 6, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2022 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.
The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-289-0459 or 1-323-794-2095 and reference access code 819614.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs more than 10,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit idexx.com.
Investor Relations:
This email address is being protected from spambots. You need JavaScript enabled to view it.
207-556-8155
Last Trade: | US$472.35 |
Daily Change: | 3.17 0.68 |
Daily Volume: | 413,912 |
Market Cap: | US$38.880B |
August 21, 2024 August 06, 2024 June 04, 2024 May 01, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB